PAVM · PAVmed Inc.
AI read · Good for PAVM
The AI's read
PAVmed removed a big capitalization overhang, issued $30M of warrants tied to EsoGuard LCD publication, and showed a much smaller GAAP loss in Q2. That combination explains the sharp rally and gives the company optionality without immediate dilution. The market has already moved +16.7% today, so some upside is priced, but the cash boost depends on warrant conversion and FDA/LCD outcomes that are not guaranteed. Balance sheet still thin at $3.8M on hand, so timing and execution matter more than the headline. We lean bullish. The setup offers asymmetric upside if EsoGuard LCD and Verus milestones hit, but long clinical timelines and contingent proceeds keep the risk real.